Roche figures MabThera safe from biosimilars till 2016

Did Roche ($RHHBY) do the right thing when it took a pass on biosimilars? Its rivals' delays in developing copies of the $7 billion blockbuster MabThera, a.k.a. Rituxan, appear to vindicate that decision, Reuters says. Report